Fabrication of gold nanoparticle for potential application in multiple myeloma

Chitta Ranjan Patra, Rajanshu Verma, Shaji K Kumar, Philip R. Greipp, Debabrata Mukhopadhyay, Priyabrata Mukherjee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The importance of nanotechnology in human health care is unquestionable. There is a growing interest to apply nanotechnology in cancer therapy, as an example. In this report, we have fabricated gold nanoparticle (AuNP), the delivery vehicle of interest, with an anti-cancer drug (Velcade) and a targeting agent (folic acid) for potential therapeutic application in multiple myeloma. Physico-chemical characterization of the nanoconjugates were carried out by UV-Visble spectroscopy exploiting the surface plasmon resonance band of AuNP, transmission electron microscopy (TEM) and studying release of radio-labeled tritiated folic acid (3FA) in a scintillation counter. The evidence of the attachment of velcade to AuNP was confirmed UV-Vis spectroscopy and studying the release of 3FA from gold-velcade-FA conjugates (Au-Vel-FA). Furthermore, the stability of Au-Vel-FA tested in PBS (phosphate buffer saline) by monitoring the release of 3FA suggested significant stability of the nanoconjugate. Functional activity of the nanoconjugate was tested by studying the apoptosis of different multiple myeloma cell lines by annexin/PI method. Apoptosis data suggested that Velcade retained its functional activity in Au-Vel-FA. In future, this strategy may be potentially utilized as an alternative approach for the treatment of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)499-507
Number of pages9
JournalJournal of Biomedical Nanotechnology
Volume4
Issue number4
DOIs
StatePublished - Dec 2008

Fingerprint

Nanoconjugates
Multiple Myeloma
Gold
Nanoparticles
Cell death
Ultraviolet spectroscopy
Nanotechnology
Fabrication
Folic Acid
Spectrum Analysis
Scintillation counters
Acids
Surface plasmon resonance
Apoptosis
Health care
Annexins
Scintillation Counting
Surface Plasmon Resonance
Phosphates
Transmission Electron Microscopy

Keywords

  • Drug delivery
  • Gold nanoparticle
  • Multiple myeloma
  • Velcade

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Fabrication of gold nanoparticle for potential application in multiple myeloma. / Patra, Chitta Ranjan; Verma, Rajanshu; Kumar, Shaji K; Greipp, Philip R.; Mukhopadhyay, Debabrata; Mukherjee, Priyabrata.

In: Journal of Biomedical Nanotechnology, Vol. 4, No. 4, 12.2008, p. 499-507.

Research output: Contribution to journalArticle

Patra, Chitta Ranjan ; Verma, Rajanshu ; Kumar, Shaji K ; Greipp, Philip R. ; Mukhopadhyay, Debabrata ; Mukherjee, Priyabrata. / Fabrication of gold nanoparticle for potential application in multiple myeloma. In: Journal of Biomedical Nanotechnology. 2008 ; Vol. 4, No. 4. pp. 499-507.
@article{a83e74338d5e4958b8930340a5371b35,
title = "Fabrication of gold nanoparticle for potential application in multiple myeloma",
abstract = "The importance of nanotechnology in human health care is unquestionable. There is a growing interest to apply nanotechnology in cancer therapy, as an example. In this report, we have fabricated gold nanoparticle (AuNP), the delivery vehicle of interest, with an anti-cancer drug (Velcade) and a targeting agent (folic acid) for potential therapeutic application in multiple myeloma. Physico-chemical characterization of the nanoconjugates were carried out by UV-Visble spectroscopy exploiting the surface plasmon resonance band of AuNP, transmission electron microscopy (TEM) and studying release of radio-labeled tritiated folic acid (3FA) in a scintillation counter. The evidence of the attachment of velcade to AuNP was confirmed UV-Vis spectroscopy and studying the release of 3FA from gold-velcade-FA conjugates (Au-Vel-FA). Furthermore, the stability of Au-Vel-FA tested in PBS (phosphate buffer saline) by monitoring the release of 3FA suggested significant stability of the nanoconjugate. Functional activity of the nanoconjugate was tested by studying the apoptosis of different multiple myeloma cell lines by annexin/PI method. Apoptosis data suggested that Velcade retained its functional activity in Au-Vel-FA. In future, this strategy may be potentially utilized as an alternative approach for the treatment of multiple myeloma.",
keywords = "Drug delivery, Gold nanoparticle, Multiple myeloma, Velcade",
author = "Patra, {Chitta Ranjan} and Rajanshu Verma and Kumar, {Shaji K} and Greipp, {Philip R.} and Debabrata Mukhopadhyay and Priyabrata Mukherjee",
year = "2008",
month = "12",
doi = "10.1166/jbn.2008.015",
language = "English (US)",
volume = "4",
pages = "499--507",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "4",

}

TY - JOUR

T1 - Fabrication of gold nanoparticle for potential application in multiple myeloma

AU - Patra, Chitta Ranjan

AU - Verma, Rajanshu

AU - Kumar, Shaji K

AU - Greipp, Philip R.

AU - Mukhopadhyay, Debabrata

AU - Mukherjee, Priyabrata

PY - 2008/12

Y1 - 2008/12

N2 - The importance of nanotechnology in human health care is unquestionable. There is a growing interest to apply nanotechnology in cancer therapy, as an example. In this report, we have fabricated gold nanoparticle (AuNP), the delivery vehicle of interest, with an anti-cancer drug (Velcade) and a targeting agent (folic acid) for potential therapeutic application in multiple myeloma. Physico-chemical characterization of the nanoconjugates were carried out by UV-Visble spectroscopy exploiting the surface plasmon resonance band of AuNP, transmission electron microscopy (TEM) and studying release of radio-labeled tritiated folic acid (3FA) in a scintillation counter. The evidence of the attachment of velcade to AuNP was confirmed UV-Vis spectroscopy and studying the release of 3FA from gold-velcade-FA conjugates (Au-Vel-FA). Furthermore, the stability of Au-Vel-FA tested in PBS (phosphate buffer saline) by monitoring the release of 3FA suggested significant stability of the nanoconjugate. Functional activity of the nanoconjugate was tested by studying the apoptosis of different multiple myeloma cell lines by annexin/PI method. Apoptosis data suggested that Velcade retained its functional activity in Au-Vel-FA. In future, this strategy may be potentially utilized as an alternative approach for the treatment of multiple myeloma.

AB - The importance of nanotechnology in human health care is unquestionable. There is a growing interest to apply nanotechnology in cancer therapy, as an example. In this report, we have fabricated gold nanoparticle (AuNP), the delivery vehicle of interest, with an anti-cancer drug (Velcade) and a targeting agent (folic acid) for potential therapeutic application in multiple myeloma. Physico-chemical characterization of the nanoconjugates were carried out by UV-Visble spectroscopy exploiting the surface plasmon resonance band of AuNP, transmission electron microscopy (TEM) and studying release of radio-labeled tritiated folic acid (3FA) in a scintillation counter. The evidence of the attachment of velcade to AuNP was confirmed UV-Vis spectroscopy and studying the release of 3FA from gold-velcade-FA conjugates (Au-Vel-FA). Furthermore, the stability of Au-Vel-FA tested in PBS (phosphate buffer saline) by monitoring the release of 3FA suggested significant stability of the nanoconjugate. Functional activity of the nanoconjugate was tested by studying the apoptosis of different multiple myeloma cell lines by annexin/PI method. Apoptosis data suggested that Velcade retained its functional activity in Au-Vel-FA. In future, this strategy may be potentially utilized as an alternative approach for the treatment of multiple myeloma.

KW - Drug delivery

KW - Gold nanoparticle

KW - Multiple myeloma

KW - Velcade

UR - http://www.scopus.com/inward/record.url?scp=58149333519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149333519&partnerID=8YFLogxK

U2 - 10.1166/jbn.2008.015

DO - 10.1166/jbn.2008.015

M3 - Article

AN - SCOPUS:58149333519

VL - 4

SP - 499

EP - 507

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 4

ER -